Humana (HUM) Expected to Announce Earnings on Tuesday

Humana (NYSE:HUM - Get Free Report) is expected to be announcing its Q4 2024 earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($2.26) per share and revenue of $28.84 billion for the quarter. Humana has set its FY 2025 guidance at 16.250-16.250 EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Humana Price Performance

Shares of Humana stock traded up $2.59 during trading hours on Wednesday, reaching $259.93. The stock had a trading volume of 2,649,639 shares, compared to its average volume of 1,691,865. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $31.30 billion, a PE ratio of 23.02, a PEG ratio of 2.11 and a beta of 0.56. The stock's 50 day moving average is $273.00 and its 200 day moving average is $295.72.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HUM. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday. TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Truist Financial increased their price objective on shares of Humana from $260.00 to $290.00 and gave the company a "hold" rating in a report on Monday, January 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $292.26.

Insiders Place Their Bets

In related news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.32% of the stock is owned by insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.